F. Seela et al. / Tetrahedron 66 (2010) 3930–3943
3941
8 (500 mg, 1.1 mmol) was dried by repeated co-evaporation with
anhydrous pyridine, and then dissolved in dry pyridine (10 mL) and
stirred with 4,40-dimethoxytrityl chloride (500 mg, 1.4 mmol) in the
evaporated, and the residue was applied to FC (silica gel, column
10ꢁ4 cm, CH2Cl2/MeOH, 80:20). Evaporation of the main zone gave
22 as a white powder (168 mg, 54%). TLC (CH2Cl2/MeOH, 80:20): Rf
0.14. UV (MeOH): lmax 244 (31 000), 260 (27 800). 1H NMR
(300 MHz, DMSO-d6); nucleoside atom numbering for the AZT-
presence of N,N-diisopropylethylamine (290 mL, 1.8 mmol) at rt. After
3 h, the solution was poured into 5% aqueous NaHCO3 (100 mL) and
extracted with CH2Cl2 (2ꢁ80 mL). The combined organic layers were
dried (Na2SO4), the solvent was evaporated and the remaining oily
residue was co-evaporated with toluene (3ꢁ10 mL) to afford a foamy
residue, which was applied to FC (silica gel, column 10ꢁ4 cm, CH2Cl2/
acetone, 90:10). Evaporation of the main zone afforded 9 as colorless
foam (707 mg, 86%). TLC (CH2Cl2/CH3OH, 90:10): Rf 0.57. UV (MeOH):
lmax 235 (34 200), 250 (sh) (26 600), 274 (19 300). 1H NMR
derived moiety, i.e., double (00) and triple (%) primed locants
d:
1.81 (s, 6H, 2ꢁH3C–C(500)); 2.12–2.20 (m, 1H, Ha–C(20)); 2.59–2.81
(m, 5H, Hb–C(20), 2ꢁH–C(2%)); 3.50–3.52 (m, 2H, 2ꢁH–C(50)); 3.60–
3.68 (m, 6H, NCH2, 4ꢁH–C(5%)); 3.76–3.77 (m, 3H, H–C(40), 2ꢁH–
C(4%)); 3.87 (s, 4H, 2ꢁNCH2); 4.21–4.23 (m, 2H, 2ꢁHO–C(5%));
4.34–4.39 (m, 1H, H–C(30)); 4.74 (‘t’, J¼5.9 Hz, 1H, HO–C(50)); 5.24–
5.34 (m, 3H, HO–C(30), 2ꢁH–C(3%)); 6.30 (‘t’, J¼6.8 Hz, 1H, H–
C(10)); 6.43 (‘t’, J¼6.5 Hz, 1H, H–C(1%)); 6.83 (br s, 2H, H2N); 7.83 (s,
2H, 2ꢁH–(C600)); 8.31 (s, 2H, 2ꢁH5-triazole); 10.71 (s, 1H, HN(5));
11.35 (s, 2H, 2ꢁHN(300)). Anal. Calcd for C39H46N16O12 (930.88): C,
50.32; H, 4.98; N, 24.07. Found: C, 49.96; H, 4.65; N, 23.74.
(300 MHz, DMSO-d6)
d
: 1.13 (d, J¼6.9 Hz, 6H, (H3C)2CH–); 2.24–2.32
(m, 1H, Ha–C(20)); 2.74–2.83 (m, 2H, Hb–C(20), CH(CH3)2); 2.97–3.07
(m, 2H, 2ꢁH–C(50)); 3.27 (s, 2H, H–C^C–); 3.46 (s, 4H, NCH2); 3.68 (s,
2H, NCH2); 3.71 (s, 6H, 2ꢁOCH3); 3.90–3.91 (m, 1H, H–C(40)); 4.46–
4.49 (m, 1H, H–C(30)); 5.33 (d, J¼4.5 Hz, 1H, HO–C(30)); 6.41 (‘t’,
J¼4.4 Hz, 1H, H–C(10)); 6.75–6.80 (m, 4H, arom. H); 7.15–7.31 (m, 9H,
arom. H); 11.90, 11.97 (2 br s, 2H, 2ꢁHN). Anal. Calcd for C44H44N6O7
(768.86): C, 68.73; H, 5.77; N, 10.93. Found: C, 68.89; H, 5.95; N, 10.79.
4.1.7. 6-Amino-1-(2-deoxy-b-D-erythro-pentofuranosyl)-1,5-dihy-
dro-3-[di(10,20,30-triazol-1-hydroxyundecyl)propargylamino]-4H-pyr-
azolo[3,4-d]pyrimidin-4-one (23). The same procedure as described
for 21, with 1 (79.2 mg, 0.20 mmol) and 5 (85.2 mg, 0.40 mmol) in
4.1.4. 6-[(2-Methylpropanoylamino)]-1-[2-deoxy-5-O-(4,40-dime-
water/THF (v/v¼1:3, 6 mL), using sodium ascorbate (200
0.20 mmol) of a freshly prepared 1 M solution in water and cop-
per(II) sulfate pentahydrate 7.5% in water (170 L, 0.05 mmol). The
mL,
thoxytrityl)-b-D-erythro-pentofuranosyl]-1,5-dihydro-{3-[di(prop-2-
ynl)amino]prop-1-ynyl}-4H-pyrazolo[3,4-d]pyrimidin-4-one-30-[(2-
cyanoethyl)-N,N-(diisopropyl)]phosphoramidite (10). A solution of 9
(550 mg, 0.70 mmol) in anhydrous CH2Cl2 (9 mL) was treated with
m
mixture was stirred vigorously in the dark at rt for 16 h. The solvent
was evaporated, and the residue was applied to FC (silica gel, col-
umn 10ꢁ4 cm, eluted with CH2Cl2/MeOH, 80:20). Evaporation of
the main zone gave 23 as a white powder (88 mg, 54%). TLC (silica
gel, CH2Cl2/MeOH, 80:20): Rf 0.77. UV (MeOH): lmax 243 (29 500),
anhydrous (iPr)2NEt (255
mL, 1.50 mmol) at rt. Then 2-cyanoethyl
diisopropylphosphoramidochloridite (230 l, 0.92 mmol) was
m
added. After 30 min, the solution was washed with saturated
NaHCO3 and extracted with CH2Cl2 (2ꢁ100 mL). The combined
organic layer was dried (Na2SO4) and the solvent was evaporated.
FC (silica gel, column 8ꢁ3 cm, CH2Cl2/acetone, 95:5) afforded 10 as
a colorless foam (564 mg, 83%). TLC (CH2Cl2/acetone, 95:5): Rf 0.38.
286 (6 200). 1H NMR (300 MHz, DMSO-d6)
d: 1.20 (s, 32H, 16ꢁCH2);
1.35–1.37 (m, 4H, 2ꢁCH2); 1.78–1.82 (m, 4H, 2ꢁCH2); 2.12–2.19 (m,
1H, Ha–C(20)); 2.64–2.72 (m, 1H, Hb–C(20)); 3.40–3.50 (m, 4H, 2ꢁH–
C(50), NCH2); 3.77–3.80 (m, 5H, 2ꢁNCH2, H–(C40)); 4.30–4.34 (m,
7H, H–C(30), 2ꢁHO–CH2–, 2ꢁ–CH2–); 4.73–4.77 (t, J¼5.1 Hz, 1H,
HO–C(50)); 5.24–5.25 (d, J¼4.2 Hz, 1H, HO–C(30)); 6.28–6.32 (‘t’,
J¼6.3 Hz, 1H, H–C(10)); 6.81 (br s, 2H, H2N); 8.13 (s, 2H, 2ꢁH5-tri-
azole); 10.73 (s, 1H, HN). Anal. Calcd for C41H66N12O6 (823.04): C,
59.83; H, 8.08; N, 20.42. Found: C, 59.95; H, 8.01; N, 20.35.
31P NMR (121.5 MHz, CDCl3)
d: 147.8, 147.9.
4.1.5. 6-Amino-1-(2-deoxy-
b-D-erythro-pentofuranosyl)-1,5-dihy-
dro-3-[di(10,20,30-triazol-1-methylbenzyl)propargylamino}-4H-pyr-
azolo[3,4-d]pyrimidin-4-one (21). To a solution of 1 (79.2 mg,
0.2 mmol) and 4 (63.8 mg, 0.48 mmol) in THF, water and tert-bu-
tanol (v/v/v¼3:1:1, 5 mL), sodium ascorbate (80
a freshly prepared 1 M solution in water and copper(II) sulfate
pentahydrate 7.5% in water (67 L, 0.02 mmol) were added. The
m
L, 0.08 mmol) of
4.1.8. 6-Amino-1-(2-deoxy-b-D-erythro-pentofuranosyl)-1,5-dihy-
dro-3-{di[10,20,30-triazol-(tetra-ethoxy-methyl)]propargylamino}-4H-
pyrazolo[3,4-d]]pyrmidin-4-one (24). The same procedure as
described for 21, with 1 (79.2 mg, 0.20 mmol) and 6 (93.3 mg,
0.40 mmol) in water/THF (v/v¼1:3, 6 mL), using sodium ascorbate
m
mixture was stirred vigorously in the dark at rt for 16 h. The solvent
was evaporated, and the residue was applied to FC (silica gel, col-
umn 10ꢁ4 cm, eluted with CH2Cl2/MeOH, 80:20). The main zone
afforded 21 as a colorless powder (104 mg, 78%). TLC (CH2Cl2/
MeOH, 80:20): Rf 0.62. UV (MeOH): lmax 243 (31 000), 285 (sh) (7
(200 mL, 0.20 mmol) of a freshly prepared 1 M solution in water and
copper(II) sulfate pentahydrate 7.5% in water (170 mL, 0.05 mmol).
The mixture was stirred vigorously in the dark at rt for 16 h. The
solvent was evaporated, and the residue was applied to FC (silica gel,
column 10ꢁ4 cm, eluted with CH2Cl2/MeOH, 80:20). Evaporation of
the main zone gave 24 as a yellow gum (67 mg, 39%). TLC (silica gel,
CH2Cl2/MeOH, 80:20): Rf 0.67. UV (MeOH): lmax 243 (26 800), 286
000). 1H NMR (300 MHz, DMSO-d6) : 2.12–2.20 (m, 1H, Ha–C(20));
d
2.64–2.73 (m, 1H, Hb–C(20)); 3.37–3.53 (m, 4H, 2ꢁH–C(50), NCH2);
3.77–3.82 (m, 5H, 2ꢁNCH2, H–C(40)); 4.37 (m, 1H, H–C(30)); 4.75 (‘t’,
J¼5.4 Hz, 1H, OH–C(50)); 5.25 (d, J¼4.2 Hz, 1H, HO–C(30)); 5.58 (s,
4H, 2ꢁNCH2); 6.31 (‘t’, J¼6.3 Hz, 1H, H–C(10)); 6.83 (br s, 2H, H2N);
7.28–7.38 (m, 10H, arom. H); 8.18 (s, 2H, 2ꢁH5-triazole)); 10.73 (s,
1H, HN). Anal. Calcd for C33H34N12O4 (662.28): C, 59.81; H, 5.17; N,
25.36. Found: C, 59.69; H, 5.22; N, 25.41. m/z (ESI-TOF) calcd for
C33H34N12O4Na (MþNaþ): 685.28; found: 685.27.
(sh) (6 700). 1H NMR (300 MHz, DMSO-d6)
d: 2.12–2.19 (m, 1H, Ha–
C(20)); 2.64–2.72 (m, 1H, Hb–C(20)); 3.21 (s, 6H, 2ꢁCH3); 3.37–3.51
(m, 28H, 2ꢁH–C(50), NCH2, 12ꢁCH2); 3.77–3.82 (m, 9H, 2ꢁCH2,
2ꢁNCH2, H–C(40)); 4.36 (m, 1H, H–C(30)); 4.52 (t, J¼4.5 Hz, 4H,
2ꢁCH2); 4.74 (t, J¼5.1 Hz, 1H, HO–C(50)); 5.24 (d, J¼3.9 Hz, 1H, HO–
C(30)); 6.30 (‘t’, J¼6.0 Hz, 1H, H–C(10)); 6.81 (br s, 2H, H2N); 8.09 (s,
2H, 2ꢁH5-triazole); 10.74 (s, 1H, HN). Anal. Calcd for C37H58N12O12
(862.93): C, 51.50; H, 6.77. Found: C, 51.69; H, 6.58.
4.1.6. 6-Amino-1-(2-deoxy-b-D-erythro-pentofuranosyl)-1,5-dihy-
dro-3-{di[10,20,30-triazol-((1,2,3,4-tetrahydro-5-methyl-2,4-dioxopyr-
imidin-1H-1-yl)-furan-3-yl)]-propargylamino}-4H-pyrazolo[3,4-
d]pyrimidin-4-one (22). The same procedure as described for 21,
with 1 (134 mg, 0.34 mmol) and 3 (216 mg, 0.81 mmol) in water/
4.1.9. ‘Double click’ reaction performed in aqueous solution. Pro-
cedure for oligonucleotides 13, 14 containing one modification site
and the azides 3 or 4. To the single-stranded oligonucleotide 13 or
THF (v/v¼1:3, 12 mL), sodium ascorbate (270
a freshly prepared 1 M solution in water and copper(II) sulfate
pentahydrate 7.5% in water (230 L, 0.0675 mmol). The mixture
was stirred vigorously in the dark at rt for 12 h. The solvent was
mL, 0.27 mmol) of
14 (5.0 A260 units) in H2O (10–20
(1:1) ligand complex (premixed from 50
lution in H2O/DMSO/t-BuOH, 4:3:1 for TBTA and 50
m
L), a mixture of a CuSO4–TBTA
L of a 20 mM stock so-
L of a 20 mM
m
m
m